⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Syndax Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Syndax Pharmaceuticals
↗Waltham, Massachusetts, USA
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for cancer patients. The company is dedicated to addressing significant unmet medical needs in oncology, particularly in hematologic malignancies such as acute leukemias and chronic graft-versus-host disease (cGVHD).
Syndax's strategy centers on advancing a pipeline of targeted therapies, including its FDA-approved products Revuforj (revumenib) and Niktimvo (axatilimab). The company emphasizes scientific excellence, collaboration, and precision medicine to improve outcomes for patients with complex cancer diagnoses.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$150M
Founded:2005
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:SNDX
Market Cap:$1.29B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb
Active Trials:0
Trial Phases:-
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Incyte (collaboration for axatilimab), Eddingpharm International (licensing for entinostat), UCB (exclusive worldwide license for axatilimab)
COMPETITION
Position:Challenger
Competitors:Incyte, Bristol Myers Squibb, GSK
LEADERSHIP
Key Executives:
Briggs W. Morrison - CEO
LINKS
Website:syndax.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Syndax Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.